News

BIO International

Join us at BIO 2024, June 3-6 in San Diego!

Dr. Sigrid Selberg joins Chemestmed

Chemestmed reports remarkable neuroprotective effects of our unique RNA m6A methyltransferase METTL3/METTL14/WTAP activators

Silver Saarva joins the Chemestmed's team

Chemestmed presentation at the 8th Neurological Disorders Summit (NDS-2023) Rome (Italy) June 12-14, 2023

Chemestmed signs a Consultancy Agreement with FreeMind Group LLC (Delaware, USA)

Chemestmed signs a Professional Service Agreement with Argentum Europe, Ltd (Jerusalem, Israel)

Chemestmed reports novel effective RNA m6A methyltransferase METTL16 inhibitors with anticancer activity

Chemestmed’s lead RNA m6A methyltransferase complex METTL3/METTL14/WTAP activator CHMA1004 is non-toxic

Chemestmed presentation at the Cold Spring Harbor (USA) meeting “Neurodegenerative Diseases: Biology & Therapeutics” November 30 - December 3, 2022

Chemestmed and University of Helsinki sign the research agreement „YTHDF small-molecule ligand screening“

Simona Selberg defends the PhD Thesis “Development of Small-Molecule Regulators of Epitranscriptomic Processes” at the University of Tartu

Service agreement with Admescope OY

First demonstration that the virus (HIV-1) replication can be affected by RNA m6A modulating small compounds.

Agreement with the University of Helsinki

Demonstration of the cancer cell antiproliferative strategy by using m6A demethylase ALKBH5 inhibitors 

Discovery of supporting the survival of dopamine neurons by RNA m6A Demethylases FTO and ALKBH5 

Chemestmed participated in the partnering eventa

Chemestmed signed research agreement